Search results
Results from the WOW.Com Content Network
A dementia charity has hailed a “historic moment” in Alzheimer’s research as a new drug has been found to reduce memory decline among patients with early-stage disease.
A study of autopsies of people diagnosed with Alzheimer's disease found that only 3% had Alzheimer's alone; 15% had a form of dementia that was not Alzheimer's, and 82% had more than one kind of ...
Alzheimer’s disease is the most common cause of dementia in the UK and affects memory, thinking and other mental abilities. It is a progressive condition which means symptoms develop gradually ...
J147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging. [1] [2] [3] [4]The approach that lead to development of the J147 drug was to screen candidate molecules for anti-aging effects, instead of targeting the amyloid plaques.
Solanezumab was safely used in combination with approved Alzheimer's disease treatment, such as acetylcholinesterase inhibitors or memantine, in the clinical trials. [1] [7] [8] Aside from Alzheimer's disease, there are other amyloid beta related diseases, in which solanezumab could be used, e.g., Down syndrome or cerebral amyloid angiopathy. [9]
The term senile dementia of the Alzheimer type (SDAT) was used for a time to describe the condition in those over 65, with classical Alzheimer's disease being used to describe those who were younger. Eventually, the term Alzheimer's disease was formally adopted in medical nomenclature to describe individuals of all ages with a characteristic ...
An estimated 6.7 million Americans ages 65 and older were living with Alzheimer’s in 2023, according to the Alzheimer’s Association. The number is projected to increase to 13.8 million by 2060.
Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. [10] It was developed by Biogen and Eisai. [11] Aducanumab is given via intravenous infusion. [5] Aducanumab was ...